|
KMID : 1141720190070020099
|
|
폐쇄성폐질환
2019 Volume.7 No. 2 p.99 ~ p.104
|
|
|
Adverse Effect of Current Treatments in Airway Disease
|
|
Park Heung-Woo
|
|
|
Abstract
|
|
|
|
Asthma and chronic obstructive airway disease (COPD) are common airway diseases for which frequently used medications include inhaled corticosteroid, long acting beta2 agonist (LABA), and long acting muscarinic antagonist (LAMA). Inhaled corticosteroid (ICS) is known to be related with hypothalamic-pituitary-adrenal (HPA) axis suppression, reduction in growth velocity, osteoporosis, diabetes, and respiratory infections. For years, the risks associated with the use of LABAs in patients with asthma have been uncertain and some health care professionals have recommended a conduction of large clinical trials to gather important safety information on these products. In December 2017, the Food and Drug Administration US removed the boxed warning on ICS/LABA combination products on the basis of results from recently completed large safety trials. In this review, evidences of medication-related adverse effects (mainly focused on the ICS) in patients with asthma and COPD is summarized.
|
|
|
KEYWORD
|
|
|
Adverse drug reaction, Asthma, Long acting beta2 agonist, Steroid
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|